Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Non-Current Debt (2016 - 2018)

Anaptysbio filings provide 3 years of Non-Current Debt readings, the most recent being $625000.0 for Q4 2018.

  • For the quarter ending Q4 2018, Non-Current Debt fell 91.73% year-over-year to $625000.0, compared with a TTM value of $625000.0 through Dec 2018, down 91.73%, and an annual FY2018 reading of $625000.0, down 91.73% over the prior year.
  • Non-Current Debt hit $625000.0 in Q4 2018 for Anaptysbio, down from $2.4 million in the prior quarter.
  • The five-year high for Non-Current Debt was $13.8 million in Q4 2016, with the low at $625000.0 in Q4 2018.
  • Median Non-Current Debt over the past 3 years was $7.6 million (2017), compared with a mean of $7.5 million.
  • The sharpest move saw Non-Current Debt tumbled 45.3% in 2017, then plummeted 91.73% in 2018.
  • Year by year, Non-Current Debt stood at $13.8 million in 2016, then plummeted by 45.3% to $7.6 million in 2017, then crashed by 91.73% to $625000.0 in 2018.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $625000.0, $2.4 million, and $4.1 million for Q4 2018, Q3 2018, and Q2 2018 respectively.